Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vilaprisan and COC Interaction Study
NCT03210246Phase 1Completed
- Sponsor
- Bayer
- Start
- Jul 2017
- Primary completion
- Jun 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Uterine Fibroids (UF) and endometriosis comparing COC + Vilaprisan with COC + Placebo (2 arms). Primary endpoints: Number of subjects with ovulation (Hoogland score = 6) or risk of ovulation (Hoogland score = 5) and Number of subjects with a Hoogland score = 4. Started Jul 2017; status: completed.
02
Drugs
vilaprisan
03
Conditions
Uterine Fibroids (UF)endometriosis
Beyond the preview
Go deeper on NCT03210246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03210246.